Floatz logo

HYDROMORPHON

Substance-Related Disorder

Endeavor HealthSmall moleculePhase 4 / ApprovedDormant
BBB
74/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

23 Active assets in the Substance-Related Disorder cohort.

Asset / SponsorPhaseRating
METHADONE
Rutgers, The State University of New Jersey
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Wake Forest University Health Sciences
Phase 4BBB
Dexmedetomidine
Kaohsiung Veterans General Hospital.
Phase 4BB
FENTANYL
University of Crete
Phase 4BB
Oxycodone
Wake Forest University Health Sciences
Phase 4BB

View all 26 →

Same molecule, other indications

HYDROMORPHON is also rated in:

cancerActive
BB
Indicative · Phase 4
68 / 100
View asset →
post-operative pain, non-human animalDormant
BB
Indicative · Phase 4
67 / 100
View asset →
hematopoietic and lymphoid cell neoplasmActive
BB
Indicative · Phase 4
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →